Watch FENC. Know when insiders buy.
One email the day a filing lands. Free.
Work order
57
WATCH · insiders 25, shorts 89
Insiders, 90 days
−$1.2M
net selling · 0 buys, 3 sells
Congress, 90 days
0 / 0
no disclosures naming it
Big money
0 / 15
none of the tracked funds disclose it
Calls on record
0
nobody we score has called it yet
MKT CAP $440.1MP/E —DIV YIELD —FCF YIELD —REV TTM $59.2M +77.8%NET INCOME −$3.3MNET CASH $21.9M52W 5.77 – 12.78NEXT EARNINGS Nov 12 EST.SEC XBRL · TTM TO Invalid Date
Financials
By quarter
| Period | Revenue | YoY | Gross margin | Operating income | Net income | YoY | EPS | Op. cash flow | Capex | Free cash flow | Filed |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Q2 2026 · Jun 30 | $17.9M | +85.2% | — | $1.7M | $2M | — | 0.05 | $50K | — | — | Aug 13 |
| Q1 2026 · Mar 31 | $15.1M | +72.6% | — | −$119K | $201K | — | 0.01 | $2.4M | — | — | Aug 13 |
| Q4 2025 · Dec 31derived | $13.8M | +73.8% | — | −$2.6M | −$4.8M | — | -0.16 | −$6M | — | — | Mar 27 |
| Q3 2025 · Sep 30 | $12.5M | +78.7% | — | −$189K | −$638K | — | -0.02 | $1.5M | — | — | Nov 13 |
| Q2 2025 · Jun 30 | $9.7M | +32.9% | — | −$2.7M | −$3.2M | — | -0.11 | −$3.7M | — | — | Aug 13 |
| Q1 2025 · Mar 31 | $8.8M | −65.5% | — | −$808K | −$1.2M | −109.1% | -0.04 | −$4.3M | — | — | Aug 13 |
| Q4 2024 · Dec 31derived | $7.9M | −18.6% | — | −$934K | −$2M | — | -0.08 | −$1.5M | — | — | Mar 27 |
| Q3 2024 · Sep 30 | $7M | +7.0% | — | −$5.2M | −$5.7M | — | -0.21 | −$2.2M | — | — | Nov 13 |
| Q2 2024 · Jun 30 | $7.3M | — | — | −$5M | −$5.6M | — | -0.20 | −$8.4M | — | — | Nov 13 |
| Q1 2024 · Mar 31 | $25.4M | — | — | $13.7M | $12.8M | — | 0.41 | $39M | — | — | Nov 13 |
| Q4 2023 · Dec 31derived | $9.7M | — | 93.0% | −$1.8M | −$2.7M | — | -0.10 | −$4.9M | — | — | Mar 26 |
| Q3 2023 · Sep 30 | $6.5M | — | 94.9% | −$1M | −$1.9M | — | -0.07 | −$2.8M | — | — | Nov 8 |
By fiscal year
| Year | Revenue | Gross margin | Operating income | Net income | Net margin | EPS | Op. cash flow | Capex | Free cash flow | Buybacks | Dividends paid |
|---|---|---|---|---|---|---|---|---|---|---|---|
| FY2025 · to Dec 31 | $44.6M | — | −$6.3M | −$9.7M | -21.8% | -0.34 | −$12.5M | — | — | — | — |
| FY2024 · to Dec 31 | $47.5M | — | $2.6M | −$436K | -0.9% | -0.02 | $27M | — | — | — | — |
| FY2023 · to Dec 31 | $21.3M | 94.1% | −$12.8M | −$16M | -75.5% | -0.60 | −$17.1M | — | — | — | — |
| FY2022 · to Dec 31 | $1.5M | 94.4% | −$22.6M | −$23.7M | -1544.9% | -0.90 | −$18.1M | — | — | — | — |
| FY2021 · to Dec 31 | — | — | −$17.2M | −$17.3M | — | -0.67 | −$14.2M | — | — | — | — |
| FY2020 · to Dec 31 | $200K | — | −$17.9M | −$18.1M | -9054.5% | -0.76 | −$15.6M | — | — | — | — |
Every number comes from FENNEC PHARMACEUTICALS INC.'s own XBRL-tagged filings with the SEC, not a data vendor. Quarters marked derived are the fiscal year minus the three reported quarters, the same way every data provider computes Q4. Restated figures replace originals as later filings arrive.